Tiny implant wipes out bladder cancer in 82% of patients
A new targeted drug delivery system called TAR-200 has shown remarkable results in a phase 2 clinical trial, eliminating tumors in 82% of patients with high-risk non-muscle-invasive bladder cancer that…